Summit Therapeutics Inc. Impairment of Intangible Assets, Finite-lived
Summit Therapeutics Inc. (SMMT) reported Impairment of Intangible Assets, Finite-lived of $5.13 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2020-11-16
| Period end | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 11 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|
| 2020-09-30 | $5.13M 10-Q · filed 2020-11-16 | ||
| 2019-12-31 | $4.38M 8-K · filed 2020-09-29 | $4.38M 10-Q · filed 2020-11-16 | |
| 2019-01-31 | $4.36M 8-K · filed 2020-09-29 | ||
| 2018-01-31 | $0.00 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |